|
1
|
Lederer DJ and Martinez FJ: Idiopathic
pulmonary fibrosis. N Engl J Med. 378:1811–1823. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Raghu G, Collard HR, Egan JJ, Martinez FJ,
Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et
al: An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary
fibrosis: Evidence-based guidelines for diagnosis and management.
Am J Respir Crit Care Med. 183:788–824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Richeldi L, Collard HR and Jones MG:
Idiopathic pulmonary fibrosis. Lancet. 389:1941–1952. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hutchinson J, Fogarty A, Hubbard R and
McKeever T: Global incidence and mortality of idiopathic pulmonary
fibrosis: A systematic review. Eur Respir J. 46:795–806. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Strand MJ, Sprunger D, Cosgrove GP,
Fernandez-Perez ER, Frankel SK, Huie TJ, Olson AL, Solomon J, Brown
KK and Swigris JJ: Pulmonary function and survival in idiopathic vs
secondary usual interstitial pneumonia. Chest. 146:775–785. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wynn TA: Integrating mechanisms of
pulmonary fibrosis. J Exp Med. 208:1339–1350. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu YM, Nepali K and Liou JP: Idiopathic
pulmonary fibrosis: Current status, recent progress, and emerging
targets. J Med Chem. 60:527–553. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kliment CR and Oury TD: Oxidative stress,
extracellular matrix targets, and idiopathic pulmonary fibrosis.
Free Radic Biol Med. 49:707–717. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kinnula VL, Fattman CL, Tan RJ and Oury
TD: Oxidative stress in pulmonary fibrosis: A possible role for
redox modulatory therapy. Am J Respir Crit Care Med. 172:417–422.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paliogiannis P, Fois AG, Collu C, Bandinu
A, Zinellu E, Carru C, Pirina P, Mangoni AA and Zinellu A:
Oxidative stress-linked biomarkers in idiopathic pulmonary
fibrosis: A systematic review and meta-analysis. Biomark Med.
12:1175–1184. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Borok Z, Buhl R, Grimes GJ, Bokser AD,
Hubbard RC, Holroyd KJ, Roum JH, Czerski DB, Cantin AM and Crystal
RG: Effect of glutathione aerosol on oxidant-antioxidant imbalance
in idiopathic pulmonary fibrosis. Lancet. 338:215–216. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hagiwara SI, Ishii Y and Kitamura S:
Aerosolized administration of N-acetylcysteine attenuates lung
fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med.
162:225–231. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Demedts M, Behr J, Buhl R, Costabel U,
Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent
F, et al: High-dose acetylcysteine in idiopathic pulmonary
fibrosis. N Engl J Med. 353:2229–2242. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Homma S, Azuma A, Taniguchi H, Ogura T,
Mochiduki Y, Sugiyama Y, Nakata K, Yoshimura K, Takeuchi M and
Kudoh S; Japan NAC Clinical Study Group, : Efficacy of inhaled
N-acetylcysteine monotherapy in patients with early stage
idiopathic pulmonary fibrosis. Respirology. 17:467–477. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sakamoto S, Itoh T, Muramatsu Y, Satoh K,
Ishida F, Sugino K, Isobe K and Homma S: Efficacy of pirfenidone in
patients with advanced-stage idiopathic pulmonary fibrosis. Intern
Med. 52:2495–2501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sakamoto S, Muramatsu Y, Satoh K, Ishida
F, Kikuchi N, Sano G, Sugino K, Isobe K, Takai Y and Homma S:
Effectiveness of combined therapy with pirfenidone and inhaled
N-acetylcysteine for advanced idiopathic pulmonary fibrosis: A
case-control study. Respirology. 20:445–452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tomioka H, Kuwata Y, Imanaka K, Hashimoto
K, Ohnishi H, Tada K, Sakamoto H and Iwasaki H: A pilot study of
aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis.
Respirology. 10:449–455. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bando M, Hosono T, Mato N, Nakaya T,
Yamasawa H, Ohno S and Sugiyama Y: Long-term efficacy of inhaled
N-acetylcysteine in patients with idiopathic pulmonary fibrosis.
Intern Med. 49:2289–2296. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Behr J, Bendstrup E, Crestani B, Günther
A, Olschewski H, Sköld CM, Wells A, Wuyts W, Koschel D, Kreuter M,
et al: Safety and tolerability of acetylcysteine and pirfenidone
combination therapy in idiopathic pulmonary fibrosis: A randomised,
double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med.
4:445–453. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martinez FJ, de Andrade JA, Anstrom KJ,
King TE Jr and Raghu G: Randomized trial of acetylcysteine in
idiopathic pulmonary fibrosis. N Engl J Med. 370:2093–2101. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun T, Liu J and Zhao de W: Efficacy of
N-Acetylcysteine in idiopathic pulmonary fibrosis: A systematic
review and meta-analysis. Medicine (Baltimore). 95:e36292016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kandhare AD, Mukherjee A, Ghosh P and
Bodhankar SL: Efficacy of antioxidant in idiopathic pulmonary
fibrosis: A systematic review and meta-analysis. EXCLI J.
15:636–651. 2016.PubMed/NCBI
|
|
23
|
Birmingham CL: Total parenteral nutrition
in the critically ill patient. Lancet. 353:1116–1117. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Langlois PL, Manzanares W, Adhikari NKJ,
Lamontagne F, Stoppe C, Hill A and Heyland DK: Vitamin C
administration in the critically ill: A systematic review and
meta-analysis. JPEN J Parenter Enteral Nutr. 43:335–346. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Manzanares W, Lemieux M, Elke G, Langlois
PL, Bloos F and Heyland DK: High-dose intravenous selenium does not
improve clinical outcomes in the critically ill: A systematic
review and meta-analysis. Crit Care. 20:3562016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fu SQ, Wang J, Yan YN and Fu SB: Effects
of acetylcysteine plus prednisone for idiopathic pulmonary fibrosis
patients. Clin Focus. 30:38–40. 2015.(In Chinese).
|
|
27
|
Huang QY: Therapeutic effect of
N-acetylcysteine combined with glucocorticoid for idiopathic
pulmonary fibrosis. Chin J Clin Ration Drug Use. 8:52–53. 2015.(In
Chinese).
|
|
28
|
Jiang AG, Lu HY and Duan DJ: Therapeutic
effect of N-acetylcysteine combined with glucocorticoid for
idiopathic pulmonary fibrosis. J Clin Med Pract. 13:69–70. 2009.(In
Chinese).
|
|
29
|
Jiang YQ and Jiang H: Therapeutic effect
of N-acetylcysteine 20 idiopathic pulmonary fibrosis patients.
Chinese Community Doctors. 10:43–44. 2008.(In Chinese).
|
|
30
|
Liu XJ: Glucocorticoid combined with
acetylcysteine for treating idiopathic pulmonary fibrosis in 58
cases. China Pharmaceuticals. 25:99–101. 2016.(In Chinese).
|
|
31
|
Liu Y: Clinical effect of budesonide
atomization inhalation combined with N-Acetylcysteine on idiopathic
pulmonary fibrosis. Pract J Cardiac Cereb Pneumal Vasc Dis.
23:74–77. 2015.(In Chinese).
|
|
32
|
Long QZ, Du J, Zhang XM, Ma W and Hui K:
Curative effect of combination of interferon-γ, n-acetylcysteine
and low dose prednisone on idiopathic pulmonary interstitial
fibrosis. J Guiyang Med Coll. 36:465–469. 2011.(In Chinese).
|
|
33
|
Lu JH and Gao JZ: Therapeutic effect of
N-acetylcysteine combined glucocorticoid on nitric oxide in
idiopathic pulmonary fibrosis patients. Chin J Lab Diagn.
17:1692–1693. 2013.(In Chinese).
|
|
34
|
Luo HJ: Effect of N-acetylcysteine on
pulmonary function of idiopathic pulmonary fibrosis patients. Chin
J Clin Pract Med. 7:60–61. 2006.(In Chinese).
|
|
35
|
Nan QQ: Influence of N-acetylcysteine on
serum interlukin-13 for idiopathic pulmonary fibrosis patients.
Chin J Prim Med Pharm. 14:1513–1514. 2007.(In Chinese).
|
|
36
|
Wang CH, Li CH and Kong B: Therapeutic
effect of N-acetylcysteine on patients with idiopathic pulmonary
fibrosis. Chin J Diffic and Compl Cas. 14:129–136. 2015.(In
Chinese).
|
|
37
|
Yang ZG, Ma XT and Wang SQ: Observation on
treating effect of N-acetylcystein on idiopathic pulmonary
fibrosis. J Med Forum. 29:18–20. 2008.(In Chinese).
|
|
38
|
Zhu JY, Zeng YQ, Yuan LJ, Chen G, Wang YL
and Hu K: Study on the treatment of idiopathic pulmonary fibrosis
with prednisone, N-acetylcysteine combined Captopril. J Yunyang Med
Coll. 28:582–584. 2009.(In Chinese).
|
|
39
|
Noble PW, Barkauskas CE and Jiang D:
Pulmonary fibrosis: Patterns and perpetrators. J Clin Invest.
122:2756–2762. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lancaster LH, de Andrade JA, Zibrak JD,
Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL,
Kirchgaessler KU and Costabel U: Pirfenidone safety and adverse
event management in idiopathic pulmonary fibrosis. Eur Respir Rev.
26:1700572017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Richeldi L, du Bois RM, Raghu G, Azuma A,
Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y,
et al: Efficacy and safety of nintedanib in idiopathic pulmonary
fibrosis. N Engl J Med. 370:2071–2082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Duecker R, Baer P, Eickmeier O, Strecker
M, Kurz J, Schaible A, Henrich D, Zielen S and Schubert R:
Oxidative stress-driven pulmonary inflammation and fibrosis in a
mouse model of human ataxia-telangiectasia. Redox Biol. 14:645–655.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hosseinzadeh A, Javad-Moosavi SA, Reiter
RJ, Yarahmadi R, Ghaznavi H and Mehrzadi S: Oxidative/nitrosative
stress, autophagy and apoptosis as therapeutic targets of melatonin
in idiopathic pulmonary fibrosis. Expert Opin Ther Targets.
22:1049–1061. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Oldham JM, Ma SF, Martinez FJ, Anstrom KJ,
Raghu G, Schwartz DA, Valenzi E, Witt L, Lee C, Vij R, et al:
TOLLIP, MUC5B, and the response to N-acetylcysteine among
individuals with idiopathic pulmonary fibrosis. Am J Respir Crit
Care Med. 192:1475–1482. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Idiopathic Pulmonary Fibrosis Clinical
Research Network, ; Raghu G, Anstrom KJ, King TE Jr, Lasky JA and
Martinez FJ: Prednisone, azathioprine, and N-acetylcysteine for
pulmonary fibrosis. N Engl J Med. 366:1968–1977. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Newton CA, Zhang D, Oldham JM, Kozlitina
J, Ma SF, Martinez FJ, Raghu G, Noth I and Garcia CK: Telomere
length and use of immunosuppressive medications in idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med. Dec 19–2018.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
